Controlling receptor pairs to explore new drug effects
A novel system for controlling dimeric receptor composition to discover unique heterodimer pharmacology
This study is looking at how certain brain receptors work together and how this affects how well drugs might help with neurological conditions, aiming to find better treatments for people who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11086120 on NIH RePORTER |
What this research studies
This research investigates how specific pairs of metabotropic glutamate receptors (mGluRs) interact and how these interactions affect drug responses. By focusing on the unique combinations of these receptors, the study aims to understand their pharmacology better, particularly in the brain where they play crucial roles in regulating excitability and plasticity. The researchers have developed a novel system to control the composition of receptor pairs, allowing for precise examination of how different receptor combinations respond to potential drug treatments. This approach could lead to more effective therapies for various neurological conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with neurological conditions that may be influenced by metabotropic glutamate receptor activity.
Not a fit: Patients with conditions unrelated to metabotropic glutamate receptors or those who do not respond to receptor-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that are more effective for neurological disorders.
How similar studies have performed: While the approach of examining receptor heterodimer pharmacology is relatively novel, there is a growing body of preclinical data suggesting that understanding these interactions could lead to significant advancements in treatment.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kammermeier, Paul J. — University of Rochester
- Study coordinator: Kammermeier, Paul J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.